The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, display ketamine-like RAAD and anti-TRD activities in rat CMS models
Open Access
- 13 June 2023
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 240 (11) , 2419-2433
Abstract
Objectives: NLX-101 and NLX-204 are highly selective serotonin 5-HT1A ‘biased’ agonists, displaying potent and efficacious antidepressant-like activity upon acute administration in models such as the forced swim test. Methods: we compared the effects of repeated administration of NLX-101, NLX-204 and ketamine in the chronic mild stress (CMS) model of depression, considered to have high translational potential, on sucrose consumption (anhedonia measure), novel object recognition (NOR; working memory measure) and elevated plus maze (EPM; anxiety measure) in male Wistar and Wistar-Kyoto rats (the latter being resistant to classical antidepressants). Results: in Wistar rats, NLX-204 and NLX-101 (0.08–0.16 mg/kg i.p.), like ketamine (10 mg/kg i.p.) dose-dependently reversed CMS-induced sucrose intake deficit from treatment Day 1, with nearly full reversal observed at the higher dose at Days 8 and 15. These effects persisted for 3 weeks following treatment cessation. In the NOR test, both doses of NLX-101/NLX-204, and ketamine, rescued the deficit in discrimination index caused by CMS on Days 3 and 17; all three compounds increased time spent in open arms (EPM) but only NLX-204 achieved statistical significance on Days 2 and 16. In Wistar-Kyoto rats, all 3 compounds were also active in the sucrose test and, to a lesser extent, in the NOR and EPM. In non-stressed rats (both strains), the three compounds produced no significant effects in all tests. Conclusions: these observations further strengthen the hypothesis that biased agonism at 5-HT1A receptors constitutes a promising strategy to achieve rapid-acting/sustained antidepressant effects combined with activity against TRD, in addition to providing beneficial effects against memory deficit and anxiety in depressed patients.Keywords
Funding Information
- Narodowe Centrum Nauki (2019/35/B/NZ7/00787)
This publication has 56 references indexed in Scilit:
- Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of ResearchCNS Drugs, 2013
- F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonistsEuropean Neuropsychopharmacology, 2010
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA AntagonistsScience, 2010
- Preferential in vivo action of F15599, a novel 5‐HT1Areceptor agonist, at postsynaptic 5‐HT1AreceptorsBritish Journal of Pharmacology, 2010
- F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activityInternational Journal of Neuropsychopharmacology, 2010
- Signal transduction and functional selectivity of F15599, a preferential post‐synaptic 5‐HT1Areceptor agonistBritish Journal of Pharmacology, 2009
- Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N-Demethylation of Ketamine in Human Liver MicrosomesDrug Metabolism and Disposition, 2002
- The role of postsynaptic 5-HT1A receptors in the anticonflict effect of ipsapironeNeuropharmacology, 1994
- Chronic mild stress-induced anhedonia: A realistic animal model of depressionNeuroscience & Biobehavioral Reviews, 1992
- A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral dataBehavioural Brain Research, 1988